Achilles Therapeutics Company
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Investors
Connections from
Headquarters:
London, England, United Kingdom
Industry:
Medical BioTech
Employee Number:
1-10
Estimated Revenue:
$10M to $50M
Investors Number:
15.0
Funding Status:
IPO
Technology:
Medical BioTech
Last Funding Type:
Grant
Founded Date:
2016-05-01
Total Funding:
212991704.0
Last Funding Date:
2022-07-21